Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Bone marrow transplantation·2026
Same author

Baricitinib and ruxolitinib use through the UK HLH Network.

The Lancet. Rheumatology·2026
Same author

Aiolos and Eos drive distinct human TH17 functional states.

Cellular and molecular life sciences : CMLS·2026
Same author

Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotype.

Frontiers in immunology·2026
Same author

Oleic Acid Promotes Treg Cell Differentiation via Autophagy Induction and Ameliorates DSS-Induced Colitis.

European journal of immunology·2026
Same author

Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Jul 24, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

669

CAR-T cells, the first pharmaceutical cell therapy.

Arian Laurence1

  • 1UCL Hospitals NHS Trust, United Kingdom.

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|July 9, 2023
PubMed
Summary

Genetically engineered adoptive cell therapies show remarkable success in treating blood cancers, challenging existing medical paradigms. However, these advanced treatments remain costly, risky, and primarily limited to specific blood disorders.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Related Experiment Videos

Last Updated: Jul 24, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

669
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Area of Science:

  • Immunology
  • Oncology
  • Personalized Medicine

Background:

  • Genetically engineered adoptive cell therapies have emerged as a significant advancement in treating haematological malignancies.
  • Their success in the 21st century has challenged established understandings in immunology and oncology.

Purpose of the Study:

  • To review the surprising success of genetically engineered adoptive cell therapies in haematological malignancy.
  • To discuss the implications for personalized medicine, the classification of cell products versus pharmaceutical drugs, and the immune system's cancer-clearing capabilities.
  • To highlight the remaining challenges associated with these therapies.

Main Methods:

  • Review of recent advancements in genetically engineered adoptive cell therapies.
  • Analysis of their impact on current medical understanding and practices.
  • Identification of limitations and challenges in current applications.

Main Results:

  • Significant success observed in genetically engineered adoptive cell therapies for blood cancers.
  • These therapies challenge traditional views on personalized medicine and the efficacy of the immune system against cancer.
  • The divide between cell-based products and traditional pharmaceutical drugs is being redefined.

Conclusions:

  • Genetically engineered adoptive cell therapies represent a breakthrough in treating haematological malignancies.
  • Despite successes, challenges such as high cost, potential hazards, and limited applicability to lymphoproliferative diseases persist.
  • Further research and development are needed to broaden accessibility and mitigate risks.